A real-world study recently reported in Journal for Immunotherapy of Cancer has shown a strong link between the occurrence of immune-related adverse events and survival in previously treated advanced or metastatic renal cell carcinoma (mRCC) patients treated with nivolumab.

Immune-related adverse events were seen in 20% of patients. The median overall survival was not reached in these patients, while in patients without immune-related adverse events median overall survival was 16.8 months.

Read more in Journal for Immunotherapy of Cancer here